Fig. 3

Evaluation of EZH2 expression in HGSOC TCGA samples. (a) Boxplots of expression levels for EZH2 mRNA, EZH2 protein and cytolytic activity (CYT) metric across the four molecular subtypes of HGSOC. Expression levels/scores were compared across groups with linear regression models adjusting for tumor purity. (b) Boxplots of EZH2 expression by response to therapy. Unadjusted group comparisons using Student’s t-test are represented. (c) EZH2 mRNA expression in platinum sensitive and platinum resistant tumors, stratified by expression of top modifier genes CARM1 and MALAT1. Unadjusted group comparisons using Student’s t-test are represented. (d) Planar filtered network of genes differentially correlated (p < 0.05, n = 1490) with EZH2 in platinum resistant compared to platinum sensitive HGSOC. Modules were identified at P < 0.05 in this network. Two distinct parent modules represent the distinct sensitive (n = 440) and resistant (n = 559) co-expression networks. Modules are identified with distinct colors for visualization. (e) Differential correlation between EZH2 and CARM1 in platinum resistant tumors. (f) GO enrichment for genes correlated with EZH2 in platinum sensitive network versus the resistant EZH2 network. mRNA and protein analyses are labeled separately. The number of genes represented in each GO Biological Process are annotated. (g) Differential correlation between EZH2 and genes that were identified in both mRNA and protein expression analysis. Statistical significance of boxplot comparisons is indicated as follows *p < 0.05, **p < 0.01, ***p < 0.0001